Sugi Predict

Sugi Predict / Compounds / SCHEMBL2493424

SCHEMBL2493424

SCHEMBL2493424

CCC(CC)c1cc(C)nc2c(-c3sc(-c4ncnn4C)nc3Br)c(C)nn12

nearest known ligand 0.34

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 3/20 0.34
▸ POLB P06746 1/20 0.34
▸ MEN1 O00255 1/20 0.32
▸ ALOX15 P16050 1/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ KDM4E B2RXH2 3/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ MAPT P10636 2/20 0.32
▸ LMNA P02545 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ CRHR1 P34998 5/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2495431 0.93 HPGD (0.33) HPGDPOLBKDM4EALDH1A1MAPT
SCHEMBL2931720 0.91 HPGD (0.35) HPGDPOLBMEN1ALOX15MAPK1
SCHEMBL2497119 0.89 HPGD (0.35) HPGDPOLBMEN1ALOX15MAPK1
SCHEMBL22958812 0.87 HPGD (0.35) HPGDPOLBMEN1ALOX15MAPK1
SCHEMBL2494028 0.83 HPGD (0.35) HPGDPOLBMEN1ALOX15MAPK1
SCHEMBL2497805 0.83 HPGD (0.38) HPGDPOLBMEN1ALOX15MAPK1
SCHEMBL22335453 0.81 HPGD (0.34) HPGDPOLBMEN1KMT2AKDM4E
SCHEMBL545488 0.81 MEN1 (0.37) HPGDPOLBMEN1ALOX15MAPK1
SCHEMBL2500610 0.81 HPGD (0.37) HPGDPOLBMEN1ALOX15MAPK1
SCHEMBL2499635 0.77 HPGD (0.34) HPGDPOLBMEN1ALOX15MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116322544-B Methods and compositions for treating polycystic ovary syndrome 云杉生物科学公司 2024-08-02 — — CN claimed
EP-4175572-A1 METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME Spruce Biosciences, Inc. (US) 2023-05-10 — — EP claimed
US-20200255436-A1 CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS AVENUE CAPITAL MANAGEMENT II, L.P. 2020-08-13 — — US claimed
US-8030304-B2 Thiazole pyrazolopyrimidines CRF1 receptor antagonists ELI LILLY AND COMPANY (US) 2011-10-04 — — US claimed
EP-2094709-B1 THIAZOLE PYRAZOLOPYRIMIDINES AS CRF1 RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2010-09-15 — — EP claimed
US-20100222339-A1 Thiazole pyrazolopyrimidines CRF1 receptor antagonists ELI LILLY AND COMPANY 2010-09-02 — — US claimed
EP-4656192-A2 TILDACERFONT AND DERIVATIVES THEREOF FOR TREATING POLYCYSTIC OVARY SYNDROME Spruce Biosciences, Inc. (US) 2025-12-03 — — EP disclosed
US-20250206733-A1 METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME AVENUE CAPITAL MANAGEMENT II, L.P. 2025-06-26 — — US disclosed
CN-118948857-A Methods and compositions for treating polycystic ovary syndrome 云杉生物科学公司 2024-11-15 — — CN disclosed
US-12098152-B2 Methods and compositions for treating polycystic ovary syndrome SPRUCE BIOSCIENCES, INC. (US) 2024-09-24 — — US disclosed
US-20240261300-A1 METHODS OF TREATING CONGENITAL ADRENAL HYPERPLASIA AVENUE CAPITAL MANAGEMENT II, L.P. 2024-08-08 — — US disclosed
CN-116322544-B Methods and compositions for treating polycystic ovary syndrome 云杉生物科学公司 2024-08-02 — — CN disclosed
US-11858932-B2 Methods and compositions for treating polycystic ovary syndrome SPRUCE BIOSCIENCES, INC. (US) 2024-01-02 — — US disclosed
US-8030304-B2 Thiazole pyrazolopyrimidines CRF1 receptor antagonists ELI LILLY AND COMPANY (US) 2011-10-04 — — US disclosed
EP-2094709-B1 THIAZOLE PYRAZOLOPYRIMIDINES AS CRF1 RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2010-09-15 — — EP disclosed
EP-2094709-B1 THIAZOLE PYRAZOLOPYRIMIDINES AS CRF1 RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2010-09-15 — — EP disclosed
US-20100222339-A1 Thiazole pyrazolopyrimidines CRF1 receptor antagonists ELI LILLY AND COMPANY 2010-09-02 — — US disclosed
US-20100222339-A1 Thiazole pyrazolopyrimidines CRF1 receptor antagonists ELI LILLY AND COMPANY 2010-09-02 — — US disclosed
US-20100222339-A1 Thiazole pyrazolopyrimidines CRF1 receptor antagonists ELI LILLY AND COMPANY 2010-09-02 — — US disclosed
WO-2008036579-A1 THIAZOLE PYRAZOLOPYRIMIDINES AS CRF1 RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2008-03-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240261300-A1 METHODS OF TREATING CONGENITAL ADRENAL HYPERPLASIA CYP21A2, HSD11B2, HSD17B2 HPGD 325/4885POLB 1004/4885MEN1 856/4885
US-20250206733-A1 METHODS AND COMPOSITIONS FOR TREATING POLYCYSTIC OVARY SYNDROME CYP17A1, SHBG, NR5A1 HPGD 2038/4885POLB 1429/4885MEN1 766/4885
US-20100222339-A1 Thiazole pyrazolopyrimidines CRF1 receptor antagonists CRHR1, CRH, CRHR2 HPGD 1864/4885POLB 4776/4885MEN1 447/4885
US-11858932-B2 Methods and compositions for treating polycystic ovary syndrome CYP17A1, SHBG, NR5A1 HPGD 2038/4885POLB 1429/4885MEN1 766/4885
US-20200255436-A1 CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS CRH, CRHR2, CRHR1 HPGD 1461/4885POLB 4411/4885MEN1 1626/4885
US-12098152-B2 Methods and compositions for treating polycystic ovary syndrome CYP17A1, SHBG, NR5A1 HPGD 2038/4885POLB 1429/4885MEN1 766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.